Latest Conference Articles

Dr. Seiko Diane Yamada, MD, the 53rd president of Society of Gynecologic Oncology (SGO), discussed her goals for SGO during her tenure.

Pharmacy Times will be covering the upcoming Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer live in Phoenix, Arizona, taking place March 18 through 21.

The annual conference includes presentations with educational opportunities related to community pharmacies, health system pharmacies, pharmacy law, public health, and more.

Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Although marketing may seem intimidating, pharmacy owners should jump in and discover what works best for their pharmacy.

Tyler Woods, PharmD, pharmacy district manager with VMC Buying Group, discussed how partnering together can help independent pharmacies obtain drugs at a lower cost.

Jen Diehl, CPA, discussed some common financial concerns for independent pharmacies and where she sees the landscape heading in the future.

Pharmacy technicians are continuing to prove their worth as pharmacies shift their focus to the future, according to Jessica Langley-Loep, executive director of education and advocacy at the National Healthcareer Association.

Tom Wheelwright, CPA, founder and CEO of WealthAbility, discussed his perspective on taxes and how pharmacies can use them to their advantage.

PDS founder and executive chairman Dan Benamoz, RPh, discussed a few of the most exciting speakers and opportunities happening during the conference.

Marci Strauss, PharmD, discussed how pharmacists are reacting to the ongoing shift toward performance-based reimbursement models.

Dan Benamoz, RPh, founder and executive chairman of PDS, and Chip Phillips, CEO, discussed their plans for the meeting and what they're focused on for the future of pharmacy.

The results of a pilot program investigating the efficacy of remote patient monitoring for patients with cancer showed that it helped to keep high-risk individuals out of the hospital.

Communication, flexibility, and virtual solutions will remain key as the COVID-19 pandemic continues.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

Judy Neville, program director of the college of pharmacy and pharmacy technician program at the University of Nebraska Medical Cancer, discusses what to look forward to for the AAPT conference in 2022.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Patients with hormone receptor-positive breast cancer doubled their median progression-free survival following a switch to fulvestrant plus palbociclib.

Patients with breast cancer treated with pyrotinib plus capecitabine had a 31% lower risk of death than those treated with lapatinib and capecitabine

New technology provides information on the benefit of adding atezolizumab to chemotherapy as a neoadjuvant treatment for patients with early high-risk and locally advanced triple-negative breast cancer.

However, active disease alone for hospitalized patients was not associated with greater odds of dying from COVID-19, nor was receiving ongoing cancer treatment.

Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.

Emicizumab-kxwh demonstrated a favorable safety profile and effective bleed control in people with mild or moderate hemophilia A without factor VIII inhibitors.

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .